Thalamus

EQS-News: PRECISIS GmbH: EASEE – ­­­World's first minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately

Retrieved on: 
Friday, September 23, 2022

Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Key Points: 
  • Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.
  • These drug-refractory patients wait an average of 22 years before they are offered further technical or surgical treatment options.
  • With this new, risk-minimized EASEE method, the treatment spectrum is expanded in the early phases of the disease."
  • EASEE is an acronym for Epicranial Application of Stimulation Electrodes for Epilepsy.

Pathway Deep in the Brain Makes It Resilient after Injury

Retrieved on: 
Wednesday, July 6, 2022

SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- For days, and even years, after someone suffers a stroke or traumatic brain injury, they have an increased risk of developing epilepsy. Now, researchers at Gladstone Institutes discovered that star-shaped cells called astrocytes in the thalamus play a key role in making mice with brain injuries susceptible to seizures.

Key Points: 
  • The team also analyzed human post-mortem brain tissue and showed that the same cells identified in mice might be altered in the thalamus of people affected by brain injury and stroke.
  • The findings, published in the journal Science Translational Medicine, suggest that targeting a protein in these cells could prevent the long-term damage that follows brain injury.
  • At the time of a stroke or traumatic brain injury, many cells at the site of the injury die almost immediately.
  • Previous studies from the team have shown, in rodent models, that activation of astrocytes in the thalamus is a common consequence of brain injury.

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Retrieved on: 
Thursday, June 9, 2022

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8th press release. The ~40 year old individual that was enrolled as the second patient in the trial exhibited clinical improvements on several measures, including positron emission tomography (PET) analysis, neurologic exam and the timed 25-foot walk test after three months of treatment. The results from the second patient are consistent with the results from the first patient which were reported in a March 10 press release. Based on the data gathered from the first two subjects, Tiziana has requested and the FDA has cleared enrollment of eight more eligible SMPS patients to receive intranasal foralumab, a fully human anti-CD3 monoclonal antibody therapy, under the Expanded Access Program.

Key Points: 
  • The second patient was diagnosed with SPMS in 2014 and over the subsequent eight years, the magnitude of his disability increased.
  • See link here for the discussion on the results for the first patient and detailed background on SPMS.
  • In the clinical sphere, investigators observed improvements in the 25-foot walk test and the neurologic exam for patient #2.
  • Intranasal Foralumabs First SPMS Patient: 3- and 6-Month Data, KOL Discussion
    On January 10, 2022, Tiziana provided a progress update for its first patient in the evaluation of intranasal foralumab in SPMS.

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Retrieved on: 
Wednesday, June 8, 2022

These findings are consistent with the results obtained from the first patient following 3-months of treatment, as previously announced on March 10, 2022.

Key Points: 
  • These findings are consistent with the results obtained from the first patient following 3-months of treatment, as previously announced on March 10, 2022.
  • These results confirm the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient.
  • The treatment with foralumab, a fully human anti-CD3 monoclonal antibody, was well-tolerated and improved clinical and PET imaging analyses.
  • Both the first and the second patient are continuing with the treatment and are in their 13th and 4th months of treatment, respectively.

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

Retrieved on: 
Tuesday, November 9, 2021

Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.

Key Points: 
  • Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.
  • Patients who received the initial dose of CST-103 showed significant increases in cerebral blood flow in multiple areas of the brain, including the hippocampus.
  • Increases in cerebral blood flow were consistent one week later in patients who received a second dose of CST-103 as monotherapy.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (RBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinson's or Alzheimers disease.

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

Retrieved on: 
Tuesday, May 11, 2021

\xe2\x80\x9cWe\xe2\x80\x99ve now been able to show that our novel capsid variants not only cross the blood brain barrier but achieve widespread transduction of multiple brain regions including the cortex, thalamus, striatum, cerebellum, brainstem and spinal cord.

Key Points: 
  • \xe2\x80\x9cWe\xe2\x80\x99ve now been able to show that our novel capsid variants not only cross the blood brain barrier but achieve widespread transduction of multiple brain regions including the cortex, thalamus, striatum, cerebellum, brainstem and spinal cord.
  • Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques.
  • All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected.
  • Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.\n'

Kochava Announces Acquisition of Thalamus

Retrieved on: 
Monday, November 9, 2020

Kochava , the leading real-time data solutions company for omni-channel attribution and measurement, today announced the acquisition of Thalamus, the largest research database of ad vendor data in the world.

Key Points: 
  • Kochava , the leading real-time data solutions company for omni-channel attribution and measurement, today announced the acquisition of Thalamus, the largest research database of ad vendor data in the world.
  • The addition of Thalamus to our product offering is another exciting step forward as we continue to diversify Kochavas exceptional solutions to the digital advertising ecosystem, said Charles Manning, Founder and CEO of Kochava.
  • We are thrilled to be joining Kochava, said Garrett Gan, Founder of Thalamus.
  • Kochava also hosts the largest independent mobile data marketplace, the Kochava Collective.

Thalamus Secures New Funding for Premier Medical Residency Management Platform; Fresco Capital, 37 Angels, Kapor Capital, and Jason Calacanis' LAUNCH Fund Lead Round

Retrieved on: 
Thursday, December 12, 2019

Thalamus is the foremost web-based, recruitment management and interview scheduling software specifically designed for application to graduate medical education (GME) training programs.

Key Points: 
  • Thalamus is the foremost web-based, recruitment management and interview scheduling software specifically designed for application to graduate medical education (GME) training programs.
  • Thalamus handles all of the confirmations, cancellations, and rescheduling, functioning as a process-specific applicant tracking system saving healthcare institutions months of workflow management.
  • Approximately 80 percent of all medical students applying to residency programs are already using Thalamus, including more than 100,000 newly minted physicians since 2013.
  • For more on Thalamus, please visit https://thalamusgme.com/ or connect with us on LinkedIn , YouTube , Facebook or Twitter

A New High-Resolution Map of How the Brain is Wired

Retrieved on: 
Wednesday, October 30, 2019

"Understanding the connectivity of the brain is fundamental for understanding how the brain works."

Key Points: 
  • "Understanding the connectivity of the brain is fundamental for understanding how the brain works."
  • To get a more detailed view of how the mammalian brain is wired, the researchers studied connections between specific classes of neurons covering two major parts of the brain, the cortex and thalamus.
  • Alterations in brain connections have been seen in Alzheimer's disease, Parkinson's and several other brain diseases and disorders.
  • The Allen Institute for Brain Science's data and tools are publicly available online at brain-map.org .

Novel Treatment Provides New Hope for Relief of Disabling Stroke Pain - Institute of Neurological Recovery

Retrieved on: 
Wednesday, October 23, 2019

The publications report rapid and sustained pain relief using a novel method of drug delivery, perispinal administration1, to accomplish effective brain delivery and relief of central pain, without surgery.

Key Points: 
  • The publications report rapid and sustained pain relief using a novel method of drug delivery, perispinal administration1, to accomplish effective brain delivery and relief of central pain, without surgery.
  • Central pain, pain due to injury of neuronal tissue, was first described after stroke in 1906.
  • Previously referred to as thalamic pain, now as central post-stroke pain, it is characteristically chronic, disabling and resistant to all treatment.
  • "This novel treatment provides new hope for the many people who have survived stroke only to find themselves left with agonizing daily pain that does not respond to any treatment," said Dr. Tobinick.